Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1765MR)

This product GTTS-WQ1765MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1765MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6247MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ137MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6369MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ2596MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ12175MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ2899MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ5679MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ5945MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW